A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

  • End date
    Dec 31, 2023
  • participants needed
  • sponsor
    Fujian Cancer Hospital
Updated on 7 February 2022


FNF-014 is a randomised, open-label, multicentre, parallel-group, phase 3 study in China to prove superiority of POF over S-1/docetaxel in postoperative adjuvant setting for pStage III gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction).

Condition Gastric Cancer Stage III
Treatment POF, Docetaxel/S-1, CAPOX/SOX/FOLFOX
Clinical Study IdentifierNCT03788226
SponsorFujian Cancer Hospital
Last Modified on7 February 2022


Yes No Not Sure

Inclusion Criteria

Age 18 to 70 years
Histologically proven in gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) of stage IIIA, IIIB, IIIC with no evidence of metastatic disease
Subjects must be able to take orally
R0 resection with D2 lymph-node dissection with al least 15 lymph nodes were examined to ensure adequate disease classification
Previously untreated except for the initial gastric resection for the primary lesion
ECOG performance status 1
Able to start chemotherapy with 42 days after gastrectomy
Hgb 9 g/dL, WBC 4000-12000/mm3, platelets 100,000/mm3
Creatine upper normal limit (UNL)
Total bilirubin 1.5 X UNL
AST, ALT and ALP 2.5 x UNL
Life expectancy estimated than 3 months
Written informed consent

Exclusion Criteria

Active double cancer
Gastrointestinal bleeding
Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant
Definite contraindications for the use of corticosteroids
Any subject judged by the investigator to be unfit for any reason to participate in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note